MicroFlow Kits are designed to provide significant benefits throughout your research process:

For screening

The MicroFlow kit’s automated system allows researchers the flexibility to perform micronucleus (MN) tests earlier in the drug discovery process. Since this in vivo test must be conducted before submission to regulatory agencies, it is in a company’s best interest to determine as early as possible if a compound is likely to induce micronuclei. Now, you have the ability to receive MN results far earlier than ever before.

For regulatory submission

MicroFlow data is accepted by the US FDA, and this method adheres to all necessary guidelines as stated by the International Workshop on Genotoxicity Test Procedures (IWGTP). Additionally, the most current Organization for Economic Co-Operation and Development (OECD) guidelines regarding micronucleus testing, Guideline 474, indicates that flow cytometry is an acceptable alternative to microscopic evaluation.

For long-term or short-term studies

The benefits of this process can be realized whether you are performing a simple short-term study, or a more complex, long-term study, with multiple time points. Because MicroFlow kits require only a small amount of blood (60-120 µl per sample) you can obtain samples at several time points throughout the life of a study. You also have the ability to receive micronucleus data along with other toxicology results and/or coordinate data between multiple studies. With so much flexibility, coupled with the ability to “piggyback” this test onto existing studies, it’s clear why so many of our clients rely on this process.